Cakmak_2022_Arch.Pharm.(Weinheim)__e2100430

Reference

Title : Synthesis, characterization, and biological evaluation of some novel Schiff bases as potential metabolic enzyme inhibitors - Cakmak_2022_Arch.Pharm.(Weinheim)__e2100430
Author(s) : Cakmak R , Basaran E , Senturk M
Ref : Arch Pharm (Weinheim) , :e2100430 , 2022
Abstract :

In this study, a series of novel Schiff base derivatives containing a pyrazolone ring (2a-e) were designed, successfully synthesized for the first time, and characterized by elemental analysis and some spectroscopic methods. These compounds were tested for their inhibitory activities on acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and the human carbonic anhydrase isoenzymes I and II (hCA I and II). All synthesized molecules indicated significant inhibition effects with IC(50) values ranging from 14.15 to 107.62 nM against these enzymes. Compound 2d showed the most potent inhibitory activity among the tested molecules toward AChE and BChE (IC(50) = 15.07 and 14.15 nM) compared to the standard drug neostigmine. We determined that the IC(50) values of the tested molecules ranged between 16.86 and 57.96 nM for hCA I and 15.24-46.21 nM for hCA II. As a consequence, we may say that some of the Schiff base derivatives may be used as potential drug candidates in later studies.

PubMedSearch : Cakmak_2022_Arch.Pharm.(Weinheim)__e2100430
PubMedID: 34994010

Related information

Citations formats

Cakmak R, Basaran E, Senturk M (2022)
Synthesis, characterization, and biological evaluation of some novel Schiff bases as potential metabolic enzyme inhibitors
Arch Pharm (Weinheim) :e2100430

Cakmak R, Basaran E, Senturk M (2022)
Arch Pharm (Weinheim) :e2100430